Quotables
"The man with a new idea is a crank until the idea succeeds."
Samuel Clemens
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7795243 | Penem prodrugs Orally bioavailable prodrugs of sulopenem, e.g., and solvates and hydrates thereof, preparation thereof, formulation thereof, and use to treat and prevent infection in mammals such as humans. This abstract is not limiting t... | 09/14/2010 |
| 7795244 | Penem prodrugs Orally bioavailable prodrugs of sulopenem, e.g., and solvates and hydrates thereof, preparation thereof, formulation thereof, and use to treat and prevent infection in mammals such as humans. This abstract is not limiting t... | 09/14/2010 |
| 7358356 | Processes for preparation of organic compounds The present invention provides a method for preparing an organic compound, which comprises a dehydration step of distilling off water from a polar organic solvent solution containing the organic compound and water to bring the concentration of water below a given le... | 04/15/2008 |
| 7282221 | Antiviral product, use and formulation thereof An antiviral product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antiviral product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosag... | 10/16/2007 |
| 7157095 | Multiple-delayed release antifungal product, use and formulation thereof An anti-fungal product is comprised of at least three delayed release dosages forms, each of which has a different release profile, with the Cmax for the anti-fungal product being reached in less than about twelve hours after initial release of anti-funga... | 01/02/2007 |
| 7125986 | Penicillanic acid derivative compounds and methods of making Compounds of formula I: wherein R1, R2, R3, R4 and n have any of the values defined in the specification, and their pharmaceutically acceptable salts, are useful for in... | 10/24/2006 |
| 7122204 | Antibiotic composition with inhibitor Antibiotic composition having four dosage forms with different release profiles providing for initial release of a beta lactam antibiotic followed by release of a beta-lactamase inhibitor, followed by release of the antibiotic followed by release of the inhibitor. I... | 10/17/2006 |
| 7115720 | Therapeutic and diagnostic compounds, compositions, and methods The invention provides a complex comprising a) a compound formula I: wherein R1, X and n have any of the values described in the specification, or a pharmaceutically acceptable salt thereof; and b) a r... | 10/03/2006 |
| 7105174 | Multiple-delayed release anti-neoplastic product, use and formulation thereof An anti-neoplastic product is comprised of at least three delayed release dosages forms, each of which has a different release profile, with the Cmax for the anti-neoplastic product being reached in less than about twelve hours after initial release of an... | 09/12/2006 |
| 7097823 | High dose radionuclide complexes for bone marrow suppression The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositi... | 08/29/2006 |
| 7094885 | Skeletal-targeted radiation to treat bone-associated pathologies The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositi... | 08/22/2006 |
| 7091197 | Beta-lactamase inhibitor prodrug Prodrugs of 6-β-hydroxymethylpenicillanic acid sulfone having the structure wherein R is H or methyl, and solvates thereof, are disclosed. Also disclosed are pharmaceutical compositions comprising a prodrug of t... | 08/15/2006 |
| 7074417 | Multiple-delayed release anti-viral product, use and formulation thereof An anti-viral product is comprised of at least three delayed release dosage forms, each of which has a different release profile, with the Cmax for the anti-viral product being reached in less than about twelve hours after initial release of anti-viral fr... | 07/11/2006 |
| 7070759 | High dose radionuclide complexes for bone marrow suppression The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositi... | 07/04/2006 |
| 7045116 | Treatment of osteomyelitis with radiopharmaceuticals This invention relates to medical uses of radiopharmaceuticals. Specifically, the present invention relates to the use of radiopharmaceuticals to treat osteomyelitis. The present invention provides improved system and methods of for the direct delivery of radiopharm... | 05/16/2006 |
| 7034035 | Fungicidal mono-, bi-, and tri-cycloheteroalkyl amides and their compositions, methods of use and preparation The present invention relates to compounds of Formula I: wherein: a) represents a 6-membered heterocyclic aromatic ring in w... | 04/25/2006 |
| 7025989 | Multiple-delayed released antibiotic product, use and formulation thereof An antibiotic product is comprised of at least three delayed release dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. ... | 04/11/2006 |
| 7018997 | Tricyclic 6-alkylidene-penems as β-lactamase inhibitors The present invention provides a compound of formula I, pharmaceutical compositions and the use thereof for the treatment of bacterial infection or disease in a patient in need thereof. wherein one of A and B denotes hy... | 03/28/2006 |
| 6929804 | Anti-fungal composition An anti-fungal product for delivering at least two different anti-fungals that is comprised of three dosage forms with different release profiles with each anti-fungal being present in at least one of the dosage forms. ... | 08/16/2005 |
| 6916801 | 7-Alkylidene-3-substituted-3-cephem-4-carboxylates as β-lactamase inhibitors The invention provides compounds of formula (I): wherein: R1-R4 and A have any of the values defined in the specification, and their pharmaceutically acceptable salts, are useful for inhibiting β... | 07/12/2005 |
| 6906054 | Compositions for inhibiting beta-lactamase The invention provides pharmaceutical compositions comprising compounds of formula I and IV: wherein R1-R11 and A have any of the values defined in the specification, and ... | 06/14/2005 |
| 6495539 | B-lactam-like chaperone inhibitors Compounds of the formula ##STR1## and the salts, esters and amides thereof wherein Z is S, SO, SO2 or O; each of R1, R2 and R3 is independently H or substituted or unsubstituted alkyl (1-10C), substituted or unsubsti... | 12/17/2002 |
| 6436398 | 2 ଲ-substituted-6-alkylidene penicillanic acid derivatives as ଲ-lactamase inhibitors Compound of formula I: ##STR1## wherein R1, R2, R3, R4 and n have any of the values defined in the specification, and their pharmaceutically acceptable salts, are useful for inhibiting ଲ-lactamase enzymes,... | 08/20/2002 |
| 6337339 | Methods and compositions for treating infection using optically pure (S)-lomefloxacin Methods and compositions are disclosed utilizing the optically pure (S)-isomer of lomefloxacin to treat bacterial infection. In particular, this compound is a potent drug for the treatment of Mycobacteria infection.... | 01/08/2002 |
| 6271222 | Penem antibacterial compounds, compositions and methods of treatment The present invention relates to penem antibacterial agents in which the releaseable liphophilic aromatic side-chain, tethered to the carbapenem nucleus via a methylene linker, necessary for anti-MRSA activity replaces the non-releaseable liphophilic side... | 08/07/2001 |
| 6156745 | 2ଲ-substituted-6-alkylidene penicillanic acid derivatives as ଲ-lactamase inhibitors Compounds of formula I: ##STR1## wherein R1, R2, R3, R4 and n have any of the values defined in the specification, and their pharmaceutically acceptable salts, are useful for inhibiting ଲ-lactamase en... | 12/05/2000 |
| 5994340 | Azetidinone derivatives as ଲ-lactamase inhibitors New 2-oxo-1-azetidine sulfonic acid derivatives with an aminoalkyl substituted "anti" (E-isomer) oxyimino group in the acylamino substituent at the 3 position of the monobactam ring. These compounds are potent inhibitors of bacterial ଲ-lactamases. T... | 11/30/1999 |
| 5885981 | Antibacterial penem esters derivatives Antibiotic penem compounds are represented by the following formula: ##STR1## wherein R represents a group of the general formula: ##STR2## in which R1 is a hydrogen atom or linear or branched C1 --C6 alkyl group... | 03/23/1999 |
| 5830889 | Antibacterial penem esters derivatives Antibiotic penem compounds are represented by the following formula: ##STR1## wherein R represents a group of the general formula: ##STR2## in which R1 is a linear or branched C1 -C6 alkyl group, R2 is... | 11/03/1998 |
| 5747483 | Penem derivatives, their preparation and pharmaceutical compositions containing them Penem derivatives of general formula (I), below, and pharmaceutically acceptable salts thereof are disclosed. ##STR1## wherein: R1 is H, C1 -C6 alkoxy, C3 -C7 cycloalkyl, or an optionally protect... | 05/05/1998 |
| 5726170 | Clavulanic acid salts The salts are prepared by reacting a benzhydrylamine of the formula I (or a salt thereof) with clavulanic acid (or a salt thereof) in solvent, and isolating the resulting salt. In formula I, each of R1 and R2 is hydrogen (preferred) ... | 03/10/1998 |
| 5703068 | Penem compounds Antibiotic penem compounds are represented by the following formula: ##STR1## wherein R represents a group of the following formula: ##STR2## in which R1 is a linear or branched, C1 -C6 alkyl group, R2... | 12/30/1997 |
| 5686441 | Penam sulfones as ଲ-lactamase inhibitors Novel 3-(substituted)-3-methyl-4-thia-1-azabicyclo3.2.0!heptane-2-carboxylate, 4,4-dioxides which are of value for use in combination with ଲ-lactam antibiotics to increase the effectiveness of the antibiotics.... | 11/11/1997 |
| 5650394 | Use of urinastatin-like compounds to prevent premature delivery The present invention provides a method of diagnosing and treating a pregnant female at risk for impending preterm delivery. The method comprises the step of diagnosing imminent preterm delivery by testing with a method that has a sensitivity of at least ... | 07/22/1997 |
| 5637579 | Penam derivatives The present invention discloses compounds having the formula ##STR1## wherein one of R1 and R2 is --COR4, --CN, --CH2 R5, halogen, --CH.dbd.CHR6 or Q and the other is hydrogen or lower... | 06/10/1997 |
| 5538962 | Antibiotic penem compounds The present invention provides a compound of the formula (I) ##STR1## wherein: R1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; R2 is hydrogen or C1-4 alkyl; Z is carboxy, sufonic acid, tetrazol-5-yl or C 1-4 ... | 07/23/1996 |
| 5506225 | Antibacterial penem compounds Antibiotic penem compounds are represented by the following formula: ##STR1## wherein R represents a physiological-hydrolyzable, ester-forming group. The physiologically hydrolyzable, ester-forming group useful in the penem compound of the present in... | 04/09/1996 |
| 5492903 | Crystalline esters of (+)-(5R, 6S)-6-[(R)-1-hydroxyethyl]-3-(3-pyridyl)-7-oxo-4-thia-1-azabicyclo[3.2.0]h e Crystalline acetoxymethyl and pivaloyloxymethyl esters of (+)-(5R, 6S)-6-[(R)-1-hydroxyethyl]-3-(3-pyridyl)-7-oxo-4-thia-1-azabicyclo-[3.2.0] hept-2-ene-carboxylic acid can be obtained by adding a poor solvent to a solution of acetoxymethyl or pivaloyloxym... | 02/20/1996 |
| 5491139 | Antimicrobial quinolonyl lactams Antimicrobial quinolonyl lactam compounds comprising a lactam-containing moiety linked, by a non-ester linking moiety, to the 3-carboxy group of a quinolone moiety. These compounds are of the formula: ##STR1## wherein (1) R3, R4... | 02/13/1996 |
| 5480880 | Penem derivatives The invention provides compounds of the general formula I ##STR1## wherein R1 is a hydrogen atom, a negative charge or an ester residue; R is: a) --(CH2)n --A--CO2 H, --(CH2)n--A--SO3 H or ... | 01/02/1996 |
